The acquisition of the SomaLogic business unit by Illumina marks a significant strategic maneuver designed to consolidate leadership in the emerging multi-omics landscape. The strategic rationale for this transaction centers on the integration of the target’s high-plex proteomics platform with the group’s world-leading sequencing technology. This fusion effectively creates a unified ecosystem capable of correlating genomic sequences with real-time protein expressions, providing researchers with an unprecedented "end-to-end" view of biological systems. For the seller, the operation allows for a definitive structural refocusing on its core microfluidics and mass cytometry divisions, while establishing a formidable capital position for future inorganic growth. The maneuver optimizes the group’s financial profile by offloading the intensive capital requirements of the proteomics services division and retaining a long-term royalty interest in future product developments. For the acquirer, the integration facilitates the scaling of proteomic-informed genomics, sharpening its focus on high-value applications in pharmaceutical R&D and clinical monitoring. Ultimately, the partnership solidifies the combined entity’s standing as a primary provider of multi-omic innovation, bridging the gap between sophisticated laboratory-scale diagnostics and industrialized scientific discovery standards.

This transaction is part of the Industry & Manufacturing industry, which currently tracks an average EBITDA multiple of 10.5x since the beginning of 2026, 3.1% increase compared to 2025. This data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.